

=====

〔国際会議発表〕

発表研究者	新潟大学 大学院医歯学総合研究科 博士課程 STA. MARIAMA. THERESE	2232106
参加会議	18 <sup>th</sup> International Conference on Alzheimer's and Parkinson's Diseases Advances in Science & Therapy AD/PD™ 2024: THEME: Striving for a better future for all those affected by neurodegenerative diseases	
開催場所	リスボン・ポルトガル	
出張期間	2024 年 3 月 3 日～2024 年 3 月 17 日（15 日間）	
発表論文	Development of a Wearable Device Aimed at Changing Cognitive Functions of Older Adults by Masticatory Behavior Change	

概 要：

Attending the AD/PD 2024 conference was a valuable experience for several reasons. The primary purpose of attending was to engage with the latest research and developments in the fields of Alzheimer's, Parkinson's, and other neurodegenerative diseases. The conference provided a platform to connect with leading experts, researchers, and practitioners, fostering collaborations and exchanging ideas that could contribute to advancing the understanding and treatment of these conditions. The conference featured presentations on the newest breakthroughs in early diagnosis, treatment, and clinical trials. Being present at such an event allowed attendees to stay updated with the most current scientific advancements and translational research, which is crucial for anyone involved in the field. AD/PD 2024 attracted over 4,000 participants from 61 countries, making it an international hub for professionals in the field. This diversity offered a unique opportunity to network with peers, exchange ideas, and establish potential collaborations that could lead to future research projects or clinical trials. The conference covered a wide range of topics, including the integration of AI and machine learning in neurodegenerative disease research, the development of brain-computer interfaces, and the ethical implications of using advanced technologies in patient care. This interdisciplinary approach enriched the learning experience by providing insights from various fields such as neuroscience, technology, and ethics. The session on artificial intelligence in early diagnosis highlighted how machine learning algorithms are being used to analyze large datasets and medical imaging to detect early signs of Alzheimer's disease. This approach has the potential to revolutionize how we diagnose and intervene in neurodegenerative diseases at earlier stages, potentially improving patient outcomes. The discussions on brain-computer interfaces provided insights into how technology can assist patients with neurodegenerative diseases in managing their symptoms. These interfaces represent a significant step forward in enhancing the quality of life for patients by offering new ways to interact with their environment despite cognitive or physical limitations. The presentation on the ethical implications of AI in neurodegenerative disease treatment was particularly thought-provoking. It underscored the importance of balancing technological advancements with ethical considerations, ensuring that patient autonomy and privacy are respected as these technologies become more integrated into healthcare. Overall, attending AD/PD 2024 was an enriching experience that offered both professional growth and a deeper understanding about research and treatment.